Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 843 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... June 24, 2025 Research with integrity – referencing work is way more than just... May 3, 2023 FDA Approves Pralsetinib for RET-Altered Thyroid Cancers December 2, 2020 Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer May 5, 2021 Load more HOT NEWS Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for... Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options...
